Details for Patent: 7,531,530

Summary for Patent: 7,531,530

Title:	Therapeutic compounds
Abstract:	The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.
Inventor(s):	Thomas Helleday, Nicola Curtin
Assignee:	Pfizer Corp Belgium , Cancer Research Technology Ltd , Pfizer Corp SRL
Application Number:	US10/565,308
Patent Claim Types: see list of patent claims	Use;

United States Patent 7,531,530: Scope of Claims and US Landscape

US Patent 7,531,530 claims methods of treating cancer tied to defects in homologous recombination (HR) genes using compounds defined by three chemical “formula” sets (I, II, III) or pharmaceutically acceptable salts, including phosphate salt embodiments. The claims cover both in vivo treatment in a mammal and ex vivo/in vivo apoptosis induction in HR-defective cancer cells, with broad gene- and cancer-type selection language.

Because the provided claim text does not include the actual structures/definitions of “Formula I/II/III” and does not include dependence relationships beyond the excerpt, the patent landscape below focuses on claim scope mechanics (what the claims cover) and how similar claim constructs typically interact in the US system (type of overlaps and freedom-to-operate risks driven by claim breadth). No assertions are made about specific competitors’ formula identities beyond what claim scope requires.

---

What is the core inventive scope in US 7,531,530?

1) Indication and biomarker lock: HR-defective cancers

Claim 1 is a method for treating cancer in a mammal where the cancer type is selected from a listed panel and the defining biomarker is:

• “a type that is caused by a genetic defect in a gene that mediates homologous recombination”
• the HR gene is selected from a list including, among others:
  XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51β, RAD51C, RAD51D, DMC1, XRCCR, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, WRN, BLM, KU70, KU80, ATM, ATR, CHK1, CHK2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9 and combinations.

Claim 9 repeats the same biomarker concept for cells rather than a mammal.

Scope effect: The claims are built to capture therapies for HR deficiency broadly, including BRCA1/2 but also many other HR/HR-adjacent genes (repair complex components, fork protection, ATR/ATM signaling, Fanconi pathway members).

2) Treatment act: diagnosis/selection + administration

Claim 1 contains two functional steps:

1. Selecting the mammal having the specified genetic defect (biomarker stratification)
2. Administering a compound defined by formula I, II, III (or salts)

This structure is typical of companion-diagnostics-style method-of-treatment claims even if no diagnostic kit is claimed. The “selecting” step materially matters for infringement analysis.

3) Chemical coverage: three formula families + salts

Claim 1 lists compounds “selected from”:

• “a compound of the formula I”
• “a compound of the formula II”
• “a compound of the formula III”
• “or a pharmaceutically acceptable salt thereof”

Claims 3 and 11 specify an additional preferred form:

• the formula I compound is “in the form of a phosphate salt.”

Scope effect: The claims cover not only the free base/parent compound (depending on how “phosphate salt” is defined in the specification) but also at least one salt form with explicit coverage.

4) Cancer-type panel is broad but still finite

Both claims reference cancer types from a list:

• breast, lung, colon, pancreas, stomach, ovary, cervix, prostate, bone, brain, skin
  (The excerpt repeats “breast” and includes “breast, lung, colon…” again; that duplication does not narrow the set.)

Scope effect: The claims cover HR-defective malignancies across multiple organs, but the set is not “any cancer.” It is limited to the listed sites.

---

What does the independent claim actually require for infringement (Claim 1 and Claim 9)?

Claim 1 (method for treating a mammal) requires all of:

1. A mammal with cancer of a type in the specified panel
2. The cancer is caused by an HR gene defect
3. The HR gene is selected from the enumerated HR list (e.g., BRCA1/2 included)
4. The method includes:
   • selecting that mammal, then
   • administering a compound of formula I/II/III or salt

Claim 9 (apoptosis induction method) requires all of:

1. Cancer cells with the specified HR gene defect
2. Cells are selected from cancers with the specified organ panel
3. HR gene is selected from the enumerated HR list
4. Steps:
   • selecting the cancer cells with the defect
   • administering a formula I/II/III compound or salt

Key practical read-through for enforcement

• These are method claims with biomarker stratification. Products alone do not infringe unless used in a manner that performs the claimed selection and administration in the claimed patient/cell population.
• The “gene list” functions as a closed enumeration in the excerpt. If a competitor uses a broader HR deficiency definition that includes genes outside the list, claim coverage depends on whether the competitor’s target gene is in the list.
• The cancer-site list is likewise closed. A therapy applied to HR-defective cancers outside the listed sites may fall outside Claim 1/9.

---

How broad are the claim gene lists and what liabilities do they create?

Gene list breadth

The HR gene list spans:

• BRCA1/BRCA2
• RAD51 family (RAD51, RAD51β, RAD51C, RAD51D, RAD52, RAD54)
• XRCC family (XRCC1, XRCC3, XRCCR)
• Nuclease/sensor components (ERCC1, XPF, XPD, MRE11)
• Fanconi anemia pathway core (FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG)
• ATM/ATR and checkpoint kinases (ATM, ATR, CHK1, CHK2)
• Bloom syndrome and recombination fork regulators (BLM, WRN, KU70, KU80)
• MRN and checkpoint related (RAD1, RAD9)
• Replication protein A components (RPA, RPA1, RPA2, RPA3)
• CTPS and MMS19 (these appear in the list though they are not classical HR core references in all frameworks)

Liability effect: A therapeutic program aimed at “HRD” as a class may still need to ensure that the targeted defect falls inside this enumeration to trigger coverage.

Duplication in the excerpt

The gene and cancer lists show duplicates (e.g., “breast” and repeated FANCD1/FANCD2/FANCE/FANCF/FANCG segments). Duplicates do not usually narrow scope unless used to limit by interpretation; they typically reflect drafting artifacts.

---

How does Claim 1 narrow in dependent claims (2 to 8)?

Claim 2

• Compound is formula I.

Coverage difference: Claim 1 covers any of formula I/II/III; Claim 2 restricts to formula I.

Claim 3

• The formula I compound is the phosphate salt form.

Coverage difference: narrows to at least one salt embodiment.

Claim 4

• Cancer is breast cancer.

Coverage difference: site-specific subset.

Claims 5 to 6

• Genetic defect is:
  • absence of a gene encoding an HR protein (Claim 5)
  • or expression defect (Claim 6)

Coverage difference: expands coverage to both null/absence and expression-level defects.

Claims 7 to 8

• HR gene is “a tumor suppressor gene”
• tumor suppressor gene is BRCA1 and/or BRCA2

Coverage difference: creates a narrower subset that anchors to BRCA1/2 as tumor suppressors.

Net effect: The dependent claims create a layered scope:

• Broad independent claim for HR gene enumeration and compound formulas I-III
• Narrower dependent claim anchors include formula I phosphate salt, breast, and BRCA1/2.

---

How does Claim 9 narrow in dependent claims (10 to 15)?

Claim 10

• Compound is formula I.

Claim 11

• Formula I is “in the form of a phosphate salt.”

Claim 12

• Genetic defect is absence of HR protein-encoding gene.

Claim 13

• Genetic defect is in expression.

Claim 14

• HR gene is a tumor suppressor gene.

Claim 15

• Tumor suppressor gene is BRCA1 and/or BRCA2
• Cancer cells are selected from the organ panel excluding “breast” in the excerpt (it lists lung, colon, pancreas, stomach, ovary, cervix, prostate, bone, brain, skin)

Net effect: Claim 9 is broad across HR-defective cancers; dependent claims create a BRCA1/2 subset and allow site-specific constraints.

---

What does this mean for the US patent landscape: where overlaps are most likely?

The infringement “hinges” are not the compound alone

Across method claims of this type, US infringement risk often clusters around:

• whether the deployed product is one of formula I/II/III (structural identity)
• whether use includes the “selecting” biomarker step and the claimed patient/cell population (HR gene defect in enumerated list)
• whether administration is in a listed cancer site population

So, in the landscape, competitors will often clear chemical structure but still create method overlap via clinical strategy and label language.

Most relevant competitor patent categories

In a US landscape assessment, overlap typically arises from one of three claim families:

1. HR-defect biomarker method-of-treatment claims
   These use “selecting” or “identifying” steps tied to BRCA1/2, RAD51, Fanconi genes, ATM/ATR, or general HRD. If their biomarker gene set intersects this patent’s enumeration, and their compound is within (or substantially equivalent to) formula I/II/III, the risk rises.

2. Compound claims plus use claims in HR-defective cancers
   Even if chemical scope differs, if another patent’s compound is close to formula I/II/III or its salts include a phosphate salt form, the landscape becomes about chemical identity and equivalents under US claim interpretation. Method claims are often asserted in tandem with composition claims.

3. Apoptosis-induction / cellular method claims
   Claim 9 is an apoptosis induction method. Competitor patents that claim “inducing apoptosis in BRCA1/2- or HR-defective tumor cells” can overlap if their gene selection and cell populations match.

Where the “selecting” step changes the landscape

US method claims that require patient selection can be harder to design around if clinical practice or protocol documentation effectively performs the selection. In practice, if a therapy is prescribed for HR gene defects that match this enumeration, the selection step may be deemed satisfied by:

• standard genetic testing workflows
• labeling language that conditions use on HR status
• clinical trial inclusion criteria

This is a key difference versus claims that omit patient selection and only require administration.

---

What is the scope of “formula I/II/III” coverage, and what does it imply for design-arounds?

The excerpt does not provide structures or definitions for:

• formula I
• formula II
• formula III
• and the exact salt definition in the specification for “phosphate salt”

Accordingly, the landscape guidance is constrained to how method claim drafting typically works:

• If formulas I to III are distinct scaffold families, a design-around usually requires moving to a new scaffold not covered by any formula.
• If salts are broadly captured as “pharmaceutically acceptable salts,” then salt form changes alone may not clear coverage unless a salt is outside “pharmaceutically acceptable” or outside the defined formula salt embodiment.
• Claim 3 and 11 explicitly mention phosphate salt for formula I. If a competitor uses formula I in a non-phosphate salt, the dependent claims may not read, but the independent claim (Claim 1/9) may still read if it covers “pharmaceutically acceptable salt thereof” generally.

Landscape implication: the most meaningful freedom-to-operate lever is usually chemical identity (not salt form), because independent claims already cover “pharmaceutically acceptable salt.”

---

How to map the claim scope to business decisions

1) Clinical development strategy

If a company’s program targets HR-defective tumors, this patent’s gene list creates a concrete mapping question:

• Which HR genes does the company test for and include?
• Which cancer sites are targeted?

Claims 1 and 9 limit both gene defects and cancer sites to enumerated sets. Clinical programs that include only partially overlapping genes or sites may reduce risk.

2) Labeling and marketing language

Because the claims require “selecting” patients/cells with the genetic defect, label language and trial protocols that make selection explicit can increase the chance that method claims are used “as claimed.” Narrow labeling to exclude specific gene subsets in the claim enumeration may reduce exposure.

3) Formulation choice

Phosphate salt embodiments are explicitly claimed for formula I. Even if a product is outside phosphate salt, independent salt coverage remains. Formulation decisions should be assessed in parallel with structural coverage.

---

US patent enforcement posture: which claims are most assertable?

• Claim 1 and Claim 9 are the principal independent claims because they cover compound formulas I-III and include broad HR gene enumeration and cancer site list.
• Claims 2-3 and 10-11 are valuable for enforcing formula I and phosphate salt embodiments.
• Claims 7-8 and 14-15 provide a narrower BRCA1/2 anchor subset if a dispute focuses on BRCA-driven enrollment and gene testing.

---

Key Takeaways

• US 7,531,530 claims method-of-treatment and apoptosis-induction in HR-defective cancers using compounds defined by Formula I/II/III and pharmaceutically acceptable salts, with explicit phosphate salt coverage for Formula I.
• The scope hinges on three claim elements: (i) enumerated cancer sites, (ii) enumerated HR gene defect list, and (iii) compound identity within Formula I/II/III plus administration with a “selecting” step.
• Dependent claims add enforcement hooks for formula I, phosphate salt, and BRCA1/2 tumor suppressor subsets.
• In the US landscape, the highest overlap risk comes from other patents that combine HR gene selection (including BRCA1/2 and other listed genes), listed cancer sites, and similar compound families or phosphate-salt embodiments.

---

FAQs

1) Is this patent about a diagnostic test?

No. The claims require a “selecting” step for patients/cells with the HR gene defect, but they do not claim a diagnostic device or kit in the excerpt.

2) Does the patent cover BRCA1/2?

Yes. Both independent and dependent claims include BRCA1 and BRCA2 within the HR gene list, and dependents specifically anchor “tumor suppressor gene is BRCA1 and/or BRCA2.”

3) Does it cover cancers outside the listed organ panel?

The excerpt limits cancer types to a finite list of sites (breast, lung, colon, pancreas, stomach, ovary, cervix, prostate, bone, brain, skin). Outside that list is not covered by Claim 1/9 as written here.

4) Does phosphate salt matter?

Yes for dependent claims: Claim 3 and Claim 11 state the formula I compound is in phosphate salt form. However, independent claims already cover pharmaceutically acceptable salts, so salt form is not the only determinant.

5) Is apoptosis induction claimed separately from mammal treatment?

Yes. Claim 9 is a distinct method directed to inducing apoptosis in HR-defective cancer cells, parallel in structure to Claim 1’s mammal treatment.

---

References

[1] United States Patent 7,531,530 (claims excerpt provided by user).

Drugs Protected by US Patent 7,531,530

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 7,531,530

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0317466.1	Jul 25, 2003
United Kingdom	0408524.7	Apr 16, 2004

PCT Information
PCT Filed	July 23, 2004	PCT Application Number:	PCT/GB2004/003183
PCT Publication Date:	February 10, 2005	PCT Publication Number:	WO2005/012305

International Family Members for US Patent 7,531,530

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	454893
Austria	516353
Australia	2004261462